|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/24 Silo Pharma, Inc. 10-K 12/31/23 69:6.7M EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.37M
2: EX-4.1 Description of the Registrant's Securities HTML 33K
3: EX-21.1 Subsidiaries List HTML 20K
4: EX-23.1 Consent on Independent Registered Accounting Firm HTML 20K
8: EX-97.1 Silo Pharma, Inc. Clawback Policy HTML 61K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
14: R1 Cover HTML 94K
15: R2 Audit Information HTML 26K
16: R3 Consolidated Balance Sheets HTML 115K
17: R4 Consolidated Balance Sheets (Parentheticals) HTML 41K
18: R5 Consolidated Statements of Operations and HTML 143K
Comprehensive Loss
19: R6 Consolidated Statements of Operations and HTML 32K
Comprehensive Loss (Parentheticals)
20: R7 Consolidated Statements of Changes in HTML 75K
Stockholders? Equity
21: R8 Consolidated Statements of Cash Flows HTML 100K
22: R9 Organization and Business HTML 29K
23: R10 Summary of Significant Accounting Policies HTML 48K
24: R11 Fair Value of Financial Instruments and Fair Value HTML 45K
Measurements
25: R12 Disposal of the Discontinued Operations of the HTML 30K
NFID Business
26: R13 Note Receivable HTML 28K
27: R14 Stockholders? Equity HTML 52K
28: R15 Concentrations HTML 24K
29: R16 Commitments and Contingencies HTML 85K
30: R17 Income Taxes HTML 34K
31: R18 Subsequent Events HTML 24K
32: R19 Pay vs Performance Disclosure HTML 33K
33: R20 Insider Trading Arrangements HTML 27K
34: R21 Accounting Policies, by Policy (Policies) HTML 82K
35: R22 Summary of Significant Accounting Policies HTML 26K
(Tables)
36: R23 Fair Value of Financial Instruments and Fair Value HTML 37K
Measurements (Tables)
37: R24 Disposal of the Discontinued Operations of the HTML 30K
NFID Business (Tables)
38: R25 Note Receivable (Tables) HTML 26K
39: R26 Stockholders? Equity (Tables) HTML 40K
40: R27 Commitments and Contingencies (Tables) HTML 35K
41: R28 Income Taxes (Tables) HTML 32K
42: R29 Organization and Business (Details) HTML 33K
43: R30 Summary of Significant Accounting Policies HTML 65K
(Details)
44: R31 Summary of Significant Accounting Policies HTML 28K
(Details) - Schedule of Potentially Dilutive
Shares
45: R32 Fair Value of Financial Instruments and Fair Value HTML 44K
Measurements (Details)
46: R33 Fair Value of Financial Instruments and Fair Value HTML 35K
Measurements (Details) - Schedule of Financial
Assets and Liabilities Measured at Fair Value on a
Recurring Basis
47: R34 Fair Value of Financial Instruments and Fair Value HTML 41K
Measurements (Details) - Schedule of Summarizes
Activity in the Company?s Short Term Investments
and Equity Investments at Fair Value
48: R35 Disposal of the Discontinued Operations of the HTML 47K
NFID Business (Details)
49: R36 Disposal of the Discontinued Operations of the HTML 33K
NFID Business (Details) - Schedule of Operating
Result of Discontinued Operations of the NFID
Business
50: R37 Note Receivable (Details) HTML 40K
51: R38 Note Receivable (Details) - Schedule of Note HTML 36K
Receivable
52: R39 Stockholders? Equity (Details) HTML 210K
53: R40 Stockholders? Equity (Details) - Schedule of Stock HTML 53K
Option Activities
54: R41 Stockholders? Equity (Details) - Schedule of HTML 59K
Warrant Activities
55: R42 Concentrations (Details) HTML 31K
56: R43 Commitments and Contingencies (Details) HTML 437K
57: R44 Commitments and Contingencies (Details) - Schedule HTML 34K
of Milestone Payments
58: R45 Commitments and Contingencies (Details) - Schedule HTML 43K
of Minimum Annual Royalty Payments
59: R46 Commitments and Contingencies (Details) - Schedule HTML 30K
of Shall Pay UMB Fees
60: R47 Commitments and Contingencies (Details) - Schedule HTML 25K
of Future Amounts Due Under Sponsored Study and
Research Agreements
61: R48 Income Taxes (Details) HTML 29K
62: R49 Income Taxes (Details) - Schedule of Income Taxes HTML 34K
at the Effective Statutory Rate and the Provision
for Income Taxes
63: R50 Income Taxes (Details) - Schedule of Net Deferred HTML 29K
Tax Asset
64: R51 Subsequent Events (Details) HTML 34K
66: XML IDEA XML File -- Filing Summary XML 122K
69: XML XBRL Instance -- ea0201957-10k_silopharma_htm XML 974K
65: EXCEL IDEA Workbook of Financial Report Info XLSX 151K
10: EX-101.CAL XBRL Calculations -- silo-20231231_cal XML 105K
11: EX-101.DEF XBRL Definitions -- silo-20231231_def XML 783K
12: EX-101.LAB XBRL Labels -- silo-20231231_lab XML 1.45M
13: EX-101.PRE XBRL Presentations -- silo-20231231_pre XML 728K
9: EX-101.SCH XBRL Schema -- silo-20231231 XSD 196K
67: JSON XBRL Instance as JSON Data -- MetaLinks 508± 728K
68: ZIP XBRL Zipped Folder -- 0001213900-24-025615-xbrl Zip 541K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 (File No. 333-276658) of our report dated March 25, 2024, relating to the consolidated financial statements of Silo Pharma, Inc. as of and for the years ended December 31, 2023 and 2022, and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ Salberg & Company, P.A.
SALBERG & COMPANY, P.A.
Boca Raton, Florida
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/25/24 | |||
| For Period end: | 12/31/23 | |||
| 12/31/22 | 10-K | |||
| List all Filings | ||||